← Back to Search

Cancer Vaccine

Idiotype Vaccine for Non-Hodgkin's Lymphoma

Phase 2

Waitlist Available

Research Sponsored by Favrille

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients that have responded with at least stable disease to their most recent chemo- or anti-CD20 antibody (Rituxan®, Zevalin, Bexxar) therapy for a minimum of 90 days and who currently have relapsed or who continue to have stable disease

Performance status (ECOG) of 0, 1 or 2

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial found that an idiotype vaccine can help to shrink tumors in patients who have relapsed after chemotherapy and/or rituximab.

Who is the study for?

This trial is for adults with grade 1 or 2 follicular B-cell lymphoma who have seen their disease stabilize or return after recent therapy. They must be in good physical condition, have normal liver and kidney function, and a certain level of white blood cells. People can't join if they've had extensive prior treatments, other cancers (except some skin cancers and cervical carcinomas), HIV, are pregnant/nursing, or have serious health issues unrelated to cancer.Check my eligibility

What is being tested?

The study tests an idiotype vaccine tailored from the patient's own lymphoma cells that came back post-chemotherapy/rituximab treatment. The goal is to see if this personalized vaccine can shrink the tumors in patients whose disease has either relapsed or remained stable.See study design

What are the potential side effects?

While specific side effects aren't listed here, vaccines like these could potentially cause reactions at the injection site, flu-like symptoms such as fever and chills, fatigue, allergic responses or might trigger autoimmune conditions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My cancer has not worsened after my last treatment and has been stable or improved for at least 90 days.

Select...

I am able to care for myself and perform daily activities.

Select...

My tumor can be or has been biopsied.

Select...

My lymphoma is a type called grade 1 or 2 follicular B-cell.

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 5Eligibility criteria met

Find a Location

Who is running the clinical trial?

FavrilleLead Sponsor

5 Previous Clinical Trials

864 Total Patients Enrolled

5 Trials studying Lymphoma

864 Patients Enrolled for Lymphoma

Media Library

Idiotype Vaccine (Cancer Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT00036426 — Phase 2

Lymphoma Clinical Trial 2023: Idiotype Vaccine Highlights & Side Effects. Trial Name: NCT00036426 — Phase 2

Idiotype Vaccine (Cancer Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00036426 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are patients being recruited for this research project at the moment?

"Unfortunately, this trial is not recruiting patients at the current moment. However, there are nearly 1800 other trials that are open for enrollment. This particular study was originally posted on March 1st 2001 and received its most recent update on June 23rd, 2005."

Answered by AI

Does this trial have an age limit? If so, what is it?

"This study is only for adults between 18 and 65 years old. There are 317 other trials available for patients that are younger and 1626 options for those who are older."

Answered by AI

Could I be a candidate for this clinical research?

"Eligible patients must be 18 years-old, have received chemo or anti-CD20 antibody therapy for at least 90 days with either stable disease or relapse, have a performance status of 0, 1 or 2, and have tumor accessible for biopsy. There must also be an additional bidimensional lesion measuring at least 2 cm in each dimension."

Answered by AI

How risky is this treatment for patients?

"There is only some data supporting the safety of this treatment, making it a 2 on our 1-3 scale."

Answered by AI

In how many different medical clinics is this research project being run today?

"Right now, there are 12 sites where this study is enrolling patients. They're situated in New york, Vista and Detroit as well as a dozen other places. If you want to limit how much travelling you have to do, it would be best to pick the location nearest you."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Idiotype Vaccine for Low-Grade Non-Hodgkin's Lymphoma

2001. "Idiotype Vaccine for Low-Grade Non-Hodgkin's Lymphoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00036426.

All > Childhood Leukemia > Vaccine